Panacea Biotec Limited · PANACEABIO
Every Panacea Biotec Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
25results judged
1read right
4read wrong
0flat / no call
20unread
32%beat the market
+1.5%avg vs market, 10d
3.9%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| strong | 4 | 1 | 3 | 0 | 25% | -0.1% | |
| favourable | 1 | 0 | 1 | 0 | 0% | -2.9% | |
| unread | 20 | 0 | 0 | 0 | — | +2.0% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
25 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 13 Aug Q1FY27 | — | unread | -0.3% | -4.5% | -3.6% | -24% | no figures |
|
› |
| 29 May Q4FY26 | strong | right | +4.3% | +31.0% | +29.7% | +17% | no figures |
|
› |
| 11 Feb Q3FY26 | strong | wrong | -1.3% | -5.2% | -3.4% | -8% | no figures |
|
› |
| 14 Nov Q2FY26 | strong | wrong | -5.6% | -9.3% | -10.3% | -2% | no figures |
|
› |
| 14 Aug Q1FY26 | favourable | wrong | -2.4% | -3.1% | -2.9% | +1% | no figures |
|
› |
| 30 May Q4FY25 | strong | wrong | -9.7% | -15.6% | -16.4% | +7% | no figures |
|
› |
| 14 Feb Q3FY25 | — | unread | -4.1% | -6.4% | -2.7% | -24% | no figures |
|
› |
| 14 Nov Q2FY25 | — | unread | +10.2% | +30.5% | +28.0% | +8% | no figures |
|
› |
| 14 Aug Q1FY25 | — | unread | +10.4% | +36.5% | +32.0% | +23% | no figures |
|
› |
| 30 May Q4FY24 | — | unread | -2.3% | +0.9% | -3.4% | -3% | no figures |
|
› |
| 14 Feb Q3FY24 | — | unread | +0.8% | +2.1% | +1.1% | -14% | no figures |
|
› |
| 11 Nov Q2FY24 | — | unread | -1.0% | +0.7% | -2.8% | +0% | no figures |
|
› |
| 12 Aug Q1FY24 | — | unread | -4.9% | +1.5% | +2.0% | +7% | no figures |
|
› |
| 31 May Q4FY23 | — | unread | -1.3% | +15.9% | +15.4% | -2% | no figures |
|
› |
| 15 Feb Q3FY23 | — | unread | -4.2% | -8.1% | -5.5% | -7% | no figures |
|
› |
| 16 Nov Q2FY23 | — | unread | -1.3% | -0.5% | -2.7% | +6% | no figures |
|
› |
| 19 May Q4FY22 | — | unread | -2.1% | -6.7% | -9.0% | +2% | no figures |
|
› |
| 15 Feb Q3FY22 | — | unread | +3.4% | +1.6% | +3.0% | — | no figures |
|
› |
| 13 Nov Q2FY22 | — | unread | -4.3% | +6.7% | +12.9% | -28% | no figures |
|
› |
| 24 Jul Q1FY22 | — | unread | -9.0% | -5.7% | -8.2% | -6% | no figures |
|
› |
| 3 Jun Q4FY21 | — | unread | -1.6% | -7.6% | -7.5% | +36% | no figures |
|
› |
| 12 Feb Q3FY21 | — | unread | -4.1% | -10.1% | -7.5% | -9% | no figures |
|
› |
| 12 Nov Q2FY21 | — | unread | — | +6.3% | +4.1% | -1% | no figures |
|
› |
| 4 Sep Q1FY21 | — | unread | -2.3% | +8.7% | +8.9% | -6% | no figures |
|
› |
| 30 Jun Q4FY20 | — | unread | -3.6% | -11.7% | -14.8% | +38% | no figures |
|
› |